Oruka Therapeutics, Inc. short interest in 2023
In 2023, Oruka Therapeutics, Inc.'s disclosed short interest ran from 1.85% of shares outstanding on 28 Apr 2023 to 1.36% on 29 Dec 2023, a change of -0.49 percentage points. The year's high was 1.92% on 15 Jun 2023 and its low 1.36% on 29 Dec 2023, averaging 1.70% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.27 days on 15 Aug 2023. Full history: Oruka Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.85% (28 Apr 2023)
- End of year
- 1.36% (29 Dec 2023)
- Change
- -0.49 pp
- High
- 1.92% (15 Jun 2023)
- Low
- 1.36% (29 Dec 2023)
- Average
- 1.70%
- Highest days to cover
- 21.27 (15 Aug 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 28 Apr 2023 | 1.85% | 16.35 | 10-K filed, results (8-K), 10-Q filed, results (8-K) |
| 15 May 2023 | 1.88% | 10.82 | |
| 31 May 2023 | 1.89% | 10.12 | |
| 15 Jun 2023 | 1.92% | 10.04 | |
| 30 Jun 2023 | 1.89% | 6.05 | |
| 14 Jul 2023 | 1.84% | 18.48 | |
| 31 Jul 2023 | 1.76% | 13.35 | 10-Q filed, results (8-K) |
| 15 Aug 2023 | 1.81% | 21.27 | |
| 31 Aug 2023 | 1.68% | 10.05 | |
| 15 Sep 2023 | 1.84% | 9.21 | |
| 29 Sep 2023 | 1.63% | 13.20 | |
| 13 Oct 2023 | 1.69% | 11.68 | |
| 31 Oct 2023 | 1.53% | 7.36 | 10-Q filed, results (8-K) |
| 15 Nov 2023 | 1.49% | 11.91 | |
| 30 Nov 2023 | 1.42% | 12.32 | |
| 15 Dec 2023 | 1.47% | 12.28 | |
| 29 Dec 2023 | 1.36% | 5.40 |
See also: Oruka Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.